Ardea Biosciences to Present Additional Data From Completed Phase …

Efficacy and Safety of Lesinurad (RDEA594), A Novel Uricosuric Agent, Given in Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Randomized , Double-Blind, Placebo- Controlled , Phase 2b Study …. Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies , risks related to regulatory approvals, delays in commencement of preclinical and clinical studies , …

Read the original: 
Ardea Biosciences to Present Additional Data From Completed Phase …

No comments yet.

TOP